Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study

Lancet

Volumn 358, Issue 9281, 2001, Pages 527-533

  Mehta, Shamir R ^a,h   Yusuf, Salim ^a   Peters, Ron J G ^b   Bertrand, Michel E ^c   Lewis, Basil S ^d   Natarajan, Madhu K ^a   Malmberg, Klas ^e   Rupprecht, Hans Jürgen ^f   Zhao, Feng ^a   Chrolavicius, Susan ^a   Copland, Ingrid ^a   Fox, Keith A A ^g  

^a MCMASTER UNIVERSITY   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d CARMEL MEDICAL CENTER   (Israel)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^g ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^h MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; GLYCOPROTEIN IIB INHIBITOR; GLYCOPROTEIN IIIA INHIBITOR; THIENO[2,3 B]PYRIDINE DERIVATIVE; TIROFIBAN; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT; TREATMENT OUTCOME;

EID: 0035908781     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)05701-4     Document Type: Article

References (30)

1. ACC/AHA guidelines for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty)
2. Antiplatelet therapy in patients undergoing percutaneous coronary intervention
3. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty
4. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty
5. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
6. The pathogenesis of coronary artery disease and the acute coronary syndromes
7. Toward a new frontier in myocardial reperfusion therapy: Emerging platelet preeminence
8. Distal embolization: A threat to the coronary artery?
9. Retrieval and analysis of particulate debris after saphenous vein graft intervention
10. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty: Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
11. Long-term clinical outcome after coronary balloon angioplasty: Identification of a population at low risk of recurrent events during 17 years of follow-up
12. Long-term treatment with a platelet glycoprotein-receptor Antagonist after percutaneous coronary revascularization: Evaluation of Oral Xemilofiban in Controlling Thrombotic Events
13. A comparison of short- and long-term outcomes for balloon angioplasty and coronary stent placement
14. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
15. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
16. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans
17. The antiaggregating and antithrombotic activity of clopidrogrel is potentiated by aspirin in several experimental models in the rabbit
18. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: Enhanced inhibitory effects of combination therapy
19. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programe: Rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease
20. Discussing hidden bias in observational studies
21. Propensity scores
22. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group
23. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
24. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban
25. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial
26. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
27. Effect of coumarins started before coronary antioplasty on acute complications and long term follow-up: A randomised trial
28. Intracoronary surface changes after Palmaz-Schatz stent implantation: Serial observations with coronary angioscopy
29. Acute and chronic tissue response to coronary stent implantation: Pathologic findings in human specimen
30. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary intervention